



Welcome to.... **Palmerston North Hospital & Tauranga Hospital** ...who are now recruiting!

Background

PantoCIN is a phase II, randomised, double-blinded, placebo controlled, crossover trial to assess Pantoprazole's effectiveness as prophylaxis against delayed Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy. The study will recruit **160 patients** from sites across New Zealand. It is managed by Cancer Trials New Zealand and funded by:



Focus on **set-up**


A checklist of requirements for set up of the study:

- Locality approval
- Māori approval
- CTRA
- GCP certificates & CVs
- Laboratory ranges & certificates
- Delegation logs
- Site initiation visit / ISF delivery
- Study drug delivery
- PantoCIN database access

Patient Reported Outcomes (PRO)

Patients complete questionnaires during their study participation. This data is used for the primary objective. Please ensure the consent process involves a discussion of the study requirements for this.

Patients can complete questionnaires online (web or app) or alternatively, by paper. Try the PRO app by accessing it through your phone app store: search for PantoCIN and use the password 'cinto21'.



Sites in set-up

- ★ Auckland City Hospital
- ★ Christchurch Hospital
- ★ Dunedin Hospital
- ★ Hawke's Bay Hospital
- ★ Rotorua Hospital
- ★ Taranaki Base Hospital
- ★ Waikato Hospital
- ★ Wellington Regional Hospital



Contact us

For general trial management queries please contact us:

Louise.clement@auckland.ac.nz



Tel: 09 923 4626

Fax: 09 373 7927

www.cancertrialsnz.ac.nz

